Eli Lilly’s CEO, Dave Ricks, has indicated that the anticipated Medicare coverage for obesity medications could significantly enhance the rollout of the company’s experimental weight loss pill, orforglipron. In an interview with CNBC, Ricks expressed optimism about the timing of Medicare’s coverage, suggesting it will occur “immediately following that launch,” and he believes this will fundamentally change the market dynamics for such treatments.
Current data shows that many patients are relying on out-of-pocket payments for competitor Novo Nordisk’s GLP-1 obesity pill, Wegovy, which launched earlier this month and has experienced a successful debut despite uneven insurance coverage. Ricks pointed out that the initial users of Wegovy appear to be primarily new adopters of GLP-1 treatments, signaling a broader acceptance and reach among patients.
Eli Lilly aims for a “full launch” of orforglipron in the second quarter, aligning efforts with Medicare’s historic decision to provide coverage for obesity medications later this year. This coverage is part of drug pricing agreements struck between Lilly, Novo, and the previous administration. Ricks noted that the inclusion of Medicare coverage would substantially lower the prescription costs, with qualifying patients potentially facing monthly copays as low as $50 for both injectable and oral GLP-1 drugs.
Health experts view Medicare’s decision as a critical development that could not only expand access to these treatments but also encourage private insurance firms to follow suit. Ricks estimates that between 20 million to 30 million Medicare beneficiaries affected by obesity and its related health complications could qualify for GLP-1 therapies, thereby significantly enlarging the pool of eligible patients.
Despite acknowledging a projected decrease in pricing as a result of the drug pricing agreements, Ricks remains optimistic about volume growth for Lilly’s drugs in the latter half of the year. He stated that the company’s performance will depend on the uptake of their treatments by Medicare patients and their market share in that segment. Further financial details regarding this initiative will be disclosed during Lilly’s fourth-quarter earnings and 2026 forecast announcement scheduled for next week.
Additionally, the pricing agreements entail commitments to launch the obesity medications at reduced cash-pay rates through a direct-to-consumer platform called TrumpRx, which is expected to empower patients further. Though TrumpRx has not yet launched as planned, Ricks highlighted that Lilly was a pioneer in direct patient sales of obesity treatments through its own LillyDirect platform, and he welcomes the broader industry effort to make medications more accessible.
